For example, the activation of the norrin/FZD4 pathway by agonistic antibodies that bind FZD4 and LRP5 or FZD4 and LRP6 (13–15) alleviate BRB defects and suppress neovascularization in oxygen-induced retinopathy models (16–18). Here, FZD4 is linked to retinal disorder.